SYNCOMF2023-10-012023-12-31 SYNCOMF2023-10-012023-12-31 SYNCOMF2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member SYNCOMF2023-12-31 SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue01Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue02Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue03Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue01Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue02Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue03Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults01Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults02Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults03Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults01Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults02Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults03Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets01Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets02Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets03Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2023-12-31in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SYNCOMF2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524470 SYNCOMF NOTLISTED Syncom Formulations (India) Limited Equity 2023-04-01 2024-03-31 2024-02-14 2024-02-06 INR Lakhs Third quarter 11:00:00 17:20:00 2024-02-14 2024-02-14 Not applicable Multi segment 2023-10-01 2023-12-31 Unaudited Consolidated 651395000.00 45554000.00 696949000.00 377465000.00 45011000.00 -27189000.00 97363000.00 10816000.00 14458000.00 85174000.00 603098000.00 93851000.00 -239000.00 93612000.00 22610000.00 985000.00 23595000.00 0.00 70017000.00 0.00 0.00 0.00 0.00 70017000.00 18571000.00 88588000.00 0.00 0.00 0.00 0.00 940000000.00 1 0.09 0.09 0.00 0.00 0.09 0.09 0.00 0.00 0.00 Multi segment 2023-04-01 2023-12-31 Unaudited Consolidated 1888142000.00 104275000.00 1992417000.00 936504000.00 220864000.00 -15542000.00 263654000.00 32790000.00 34246000.00 280432000.00 1752948000.00 239469000.00 -239000.00 239230000.00 55017000.00 5116000.00 60133000.00 0.00 179097000.00 0.00 0.00 0.00 0.00 179097000.00 51682000.00 230779000.00 0.00 0.00 0.00 0.00 940000000.00 1 0.25 0.25 0.00 0.00 0.25 0.25 0.00 0.00 0.00 OTHER EXPENSES 85174000.00 OTHER EXPENSES 280432000.00 Pharmaceutical Drugs & Formulations 675587000.00 Renting of Property 9923000.00 Trading of Commodities 11439000.00 Pharmaceutical Drugs & Formulations 1876354000.00 Renting of Property 30322000.00 Trading of Commodities 85741000.00 696949000.00 1992417000.00 0.00 0.00 696949000.00 1992417000.00 Pharmaceutical Drugs & Formulations 95071000.00 Renting of Property 9468000.00 Trading of Commodities -111000.00 Pharmaceutical Drugs & Formulations 243205000.00 Renting of Property 28958000.00 Trading of Commodities -143000.00 104428000.00 272020000.00 10816000.00 32790000.00 0.00 1. The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/02/2024 2. These above results have been prepared in compliance with the Indian Accounting Standard (referred to as Ind AS ) as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. 3. The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required. 4. As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31st December, 2023. The report does not have any impact on the above results and notes which needs explanation. 5. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 6. The company has generated (From FY-2020-21 to 2022-23) Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 3994.16 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 37.34 Lakhs will be used in the subsequent period. There is no deviation in the project till 31st Dec 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately 0.00 93612000.00 239230000.00 Pharmaceutical Drugs & Formulations 3568064000.00 Renting of Property 474064000.00 Trading of Commodities 4127000.00 4046255000.00 0.00 4046255000.00 Pharmaceutical Drugs & Formulations 1234675000.00 Renting of Property 16391000.00 Trading of Commodities 5211000.00 1256277000.00 0.00 1256277000.00 0.00 0.00 ITEMS THAT WILL BE RECLASSIFIED TO PROFIT AND LOSS 18571000.00 ITEMS THAT WILL BE RECLASSIFIED TO PROFIT AND LOSS 51682000.00 18571000.00 51682000.00 0.00 0.00